Latest News

Mini-PCNL has higher stone-free rate than ureteroscopy and similar cost burden
Mini-PCNL has higher stone-free rate than ureteroscopy and similar cost burden

May 23rd 2023

The trial assessed outcomes in patients who had kidney stones between 1 to 2 cm.

blurred photo of a clinic hallway
PCNL equipment whiteboard shown to improve surgical team communication

April 17th 2023

blurred photo of a clinic hallway
CBD oil does not reduce pain in patients after ureteroscopy

March 22nd 2023

human kidneys on a blue background with a yellow/orange glow in the middle
ED visits and hospital admissions continue to rise up to 120 days after stone procedures

March 20th 2023

MUSC Kidney Stone Center ensures patients with kidney stones get treatment within 24 hours
MUSC Kidney Stone Center ensures patients with kidney stones get treatment within 24 hours

February 12th 2023

Latest CME Events & Activities

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future

View More

Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC

View More

Updates in Therapeutic Strategies for Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach to Optimal Management of Adverse Effects, featuring Counseling Vignettes

View More

How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer

View More

7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)

10/21/2023

View More

How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer

View More

How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)

10/21/2023

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future

View More

Updates in Therapeutic Strategies for Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach to Optimal Management of Adverse Effects, featuring Counseling Vignettes

View More

Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC

View More

© 2023 MJH Life Sciences

All rights reserved.